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Abstract
Background: Although an effective measles vaccine has been available for almost 40 years, in 2000
there were about 30 million measles infections worldwide and 777,000 measles-related deaths. The
history of smallpox suggests that achieving measles eradication depends on several factors; the
biological characteristics of the organism; vaccine technology; surveillance and laboratory
identification; effective delivery of vaccination programmes and international commitment to
eradication.
Discussion: Like smallpox, measles virus has several biological characteristics that favour
eradication. Humans are the only reservoir for the virus, which causes a visible illness and infection
leading to life-long immunity. As the measles virus has only one genetic serotype which is relatively
stable over time, the same basic vaccine can be used world-wide. Vaccination provides protection
against measles infection for at least 15 years, although efficacy may be reduced due to host factors
such as nutritional status. Measles vaccination may also confer other non-specific health benefits
leading to reduced mortality. Accurate laboratory identification of measles cases enables enhanced
surveillance to support elimination programmes. The "catch-up, keep-up, follow-up" vaccination
programme implemented in the Americas has shown that measles elimination is possible using
existing technologies. On 17th October 2003 the "Cape Town Measles Declaration" by the World
Health Organisation and the United Nations Childrens Fund called on governments to intensify
efforts to reduce measles mortality by supporting universal vaccination coverage and the
development of more effective vaccination.
Summary: Although more difficult than for smallpox, recent experience in the Americas suggests
that measles eradication is technically feasible. Growing international support to deliver these
programmes means that measles, like smallpox, may very well become a curiosity of history.
Background
On the 26th October 1977, the last known case of natu-
rally acquired smallpox occurred in Somalia [1]. This
promised a new era in which many infectious diseases
would be eradicated. However, nearly a quarter of a cen-
tury later, 1.7 million children die each year from vaccine
preventable diseases, nearly half due to measles (Figure.
1). Although an effective measles vaccine has been availa-
ble for almost 40 years [2], in 2000 there were about 30
million measles infectious worldwide and 777,000 mea-
sles-related deaths [3]; measles is the 5th leading cause of
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death in children under the age of five [4]. One might
therefore wonder why have we not eradicated measles?
The history of smallpox has shown us that several factors
must be considered in order to eradicate an infectious dis-
ease [5-7]; the biological characteristics of the organism;
vaccine technology; surveillance and laboratory identifi-
cation; effective delivery of vaccination programmes and
international commitment to eradication. I will consider
each of these elements, their implications for measles
eradication and draw on lessons from smallpox
eradication.
Discussion
Biological characteristics of the measles virus
Measles virus is a spherical single-stranded RNA virus
belonging to the paramyxoviridae family [2]. It is spread
by airborne droplets causing rash, cough and fever which
lasts for several days [8]. Although there is no treatment,
most infected individuals recover by themselves. How-
ever, complications due to pneumonia occur in 2–27% of
cases causing 56–86% of all measles deaths [2]. Less com-
monly, measles infection can cause serious neurological
complications [2]. Compared to smallpox, the measles
virus is considerably more contagious, capable of causing
large outbreaks even in populations with high vaccine
coverage [9]. Nevertheless, measles shares several biologi-
cal characteristics with smallpox which favour eradication
[2,7,10]: humans are the only reservoir for the virus (i.e.
animals are not infected); measles causes a visible illness;
infection leads to life-long immunity; cases often occur at
regular intervals enabling the targeting of interventions;
measles virus has only one genetic serotype which is rela-
tively stable over time [2]; an effective vaccine is available
and accurate laboratory identification is possible.
Vaccine technology
The limited variability of the measles genome means that
the same basic vaccine can be used worldwide [2]. A single
dose of the vaccine provides about 90% protection, which
is increased to about 99% with a second dose [11]. How-
ever vaccination programmes in developing countries
may not achieve such high levels of protection, either
because of cold chain failures [12] or host factors such as
poor nutritional status [13,14]. Antibody titres following
vaccination are lower than following infection with wild
measles virus [2] and decrease over time. Nevertheless,
vaccination can provide immunological memory against
wild measles virus for at least 15 years [15]. However, in
contrast to immunity following infection by wild measles
virus, protection may not be life-long [15]. Infection due
to wild virus amongst individuals with reduced vaccine-
induced protection may be subclinical or cause milder ill-
ness than for individuals who are unvaccinated or did not
seroconvert following vaccination [2].
Because of the highly infectious nature of the virus,
between 90–95% vaccination coverage is needed to halt
measles transmission [10]. An additional difficulty is that
maternal antibodies interfere with the vaccine, reducing
seroconversion in infants between 6–9 months old [16].
Despite concerns in some industrialised countries about
the safety of the measles vaccine, adverse vaccine-associ-
ated events are rare [9,17]. A study of 20 million children
and adolescents receiving measles vaccination in the UK,
Canada, Australia, South Korea, Costa Rica, Romania and
New Zealand identified no vaccine-related deaths [9]. The
risk of encephalitis was estimated to be 1 per 1 million
doses and acute anaphylaxis less than 1 per 1 million
doses [9].
Epidemiological research further suggests that measles
vaccination (and mild measles illness) may actually con-
fer non-specific health benefits leading to reduced child-
hood mortality rates [18,19]. The reduction in non-
measles mortality following vaccination is greater in girls
than boys [20]. Although there is currently no biological
explanation for this, greater protection against other infec-
tions may be caused by immunological stimulation due
to the measles virus or vaccine [18]. If this is indeed the
case, the implications would be that continued measles
vaccination may be beneficial even after wild measles
virus is eradicated [18].
Measles vaccination is currently given by injection, which
requires skilled personnel to administer, thereby making
widespread coverage more difficult. Injections are also
associated with an increased risk of blood borne disease
(e.g. HIV, hepatitis), risk of infection at the injection site
and they lead to large amounts of medical waste [12,21].
As efforts to eradicate smallpox were transformed by the
Proportional mortality (1.7 million worldwide) due to vac-cine p eventable diseases among children (2000)Figure 1
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development of better vaccine delivery techniques [5,7], a
new aerosolised measles vaccine promises to transform
the battle against the measles vaccine [21]. The new
approach, which is non-invasive and requires only mini-
mal training to administer, has been successfully trailed in
Mexico and is hoped to be in widespread use by 2009
[21]. Further research using a wide range of vaccine tech-
nologies such as DNA vaccines, bacterial vectors and viral
vectors is also being undertaken to develop effective vac-
cines for infants younger than 6 months old [21].
Surveillance and laboratory identification
A strong measles surveillance network is vital to ensure
that vaccine efficacy and coverage are maintained and that
outbreaks or reservoirs of disease are identified [22,23].
Identification of measles infection can be made on clini-
cal grounds by experienced clinicians. However, experi-
ence with smallpox has shown that as the incidence of
disease decreases it becomes increasingly important to
investigate every suspected case (case-based surveillance)
and provide laboratory confirmation. In order to achieve
this, the World Health Organisation is establishing a Glo-
bal Measles Laboratory Network, which will develop local
reference laboratories and train staff [24]. Laboratory
identification of measles can be performed using rela-
tively simple methods to test for the presence of measles-
specific antibodies in the blood [25]. Where more com-
plex genetic techniques are available, identification of dif-
ferent virus strains can show whether infections are due to
local transmission or importation [24,25]. However,
many poorer countries currently still lack sufficient
resources to develop enhanced measles surveillance and
laboratory diagnosis.
Effective delivery of vaccination programmes
In 2000, vaccination programmes worldwide achieved
about 80% coverage with one dose of measles vaccine
(Table 1). This was lowest in the African region (65%) and
highest in the American (91%) and European (92%)
regions. Only 74 countries (35%) achieved greater than
90% coverage while sixteen countries achieved coverage
below 50% [4]. Since 2001 81% of countries have been
offering a second opportunity for measles vaccination [4].
These efforts have had a significant impact on measles
morbidity, preventing an estimated 1 million measles-
related deaths per year compared to pre-vaccination levels
(Table 1) [4].
However, the Americas is the only region that has made
significant progress towards measles eradication; no
known indigenous measles transmission has occurred
since November 2002 [22]. This has been achieved by
implementing a "catch-up, keep-up, follow-up" pro-
gramme [10,22]. The programme begins with a one-time
"catch-up" mass-vaccination campaign aimed at all
children aged 1–14 years old (individuals over 15 years
are considered to have acquired natural immunity and
infants are not included). Routine vaccination is given to
all individuals at 12 months of age to "keep-up" coverage
and periodic mass-vaccination campaigns provide a sec-
ond "follow-up" opportunity. The universal second
opportunity is important because children who miss their
first vaccination and those individuals not protected by
the first vaccination gradually build-up a population of
susceptible individuals able to sustain transmission if the
virus is re-introduced. Epidemiological studies suggest
that these 'cycles of abundance' occur about every four
years [5,22]. However, the need to achieve almost univer-
sal coverage of large geographical areas to halt measles
transmission has meant that follow-up vaccinations pro-
grammes targeted at urban centres or limited geographical
areas have sometimes been unsuccessful [26].
Implementing "catch-up, keep-up, follow-up" pro-
grammes present several challenges; the high cost can not
be met by many countries while donor dependency may
create unsustainable programmes in the longer term; poor
healthcare infrastructure, limited access to rural areas and
vaccine management are likely to reduce vaccination cov-
erage; competing national and international interests may
Table 1: Number of deaths, vaccination coverage and deaths prevented by WHO region (2000)
Region No of deaths Vaccination coverage (%) Deaths prevented
African 453,000 65 384,960
American 0 91 148,852
Eastern Mediterranean 81,000 79 129,769
European 7,000 92 28,692
Southeast Asia 202,000 83 256,633
Western Pacific 34,000 86 126,132
Total 777,000 80 1,071,938
Source: Adapted from Henao-Restrepo (2003) [4]
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divert necessary financial and technical resources; cam-
paigns may interrupt or divert resources away from rou-
tine vaccination programmes thereby reducing their
efficiency; adopting a second opportunity for measles vac-
cination for all children will almost double the demand
for measles vaccine and without adequate demand fore-
casting, sufficient quantities of vaccine may not be availa-
ble; political and social upheaval such as armed conflict or
natural disasters may interrupt on-going programmes
[9,12,27].
International commitment to eradication
In 2001 the World Health Organisation (WHO) and
United Nations Children's Fund (UNICEF) published a
joint strategic plan for 2001–2005 [23]. The strategy aims
to reduce measles mortality in 2005 by 50% compared to
1999 levels and to maintain interruption of indigenous
measles transmission in large geographic areas. The strat-
egy was endorsed in 2003 by the World Health Assembly,
which includes 192 member states. On 17th October
2003, a meeting of WHO and UNICEF produced the
"Cape Town Measles Declaration" calling on govern-
ments to intensify efforts to meet the Strategy's goal of
mortality reduction [28]. Other initiatives, such as the
Global Alliance for Vaccines and Immunisations (GAVI)
and the Measles Initiative, are helping to ensure adequate
vaccine provision [29,30]. At the end of the strategic plan
in 2005, WHO and UNICEF will review progress and
assess the feasibility of global measles eradication.
Conclusions
Global eradication of measles is more difficult than for
smallpox, mostly due to the greater virulence of the virus,
needing almost universal vaccine coverage. However, suc-
cess in the Americas has shown that measles eradication is
technically feasible using existing vaccines and vaccina-
tion programmes. Growing international support, to
deliver these programmes means that measles, like small-
pox, can very well become a curiosity of history.
Summary
▪ Although an effective vaccine has been available for
almost 40 years, in 2000 there were about 30 million
measles infections and 777,000 measles-related deaths
worldwide.
▪ The history of smallpox highlights several important fac-
tors for disease eradication; the biological characteristics
of the organism; vaccine technology; surveillance and
laboratory identification; effective delivery of vaccination
programmes and international commitment to
eradication.
▪ Although more difficult than for smallpox, considera-
tion of these factors and recent experience in the Americas
suggests that measles eradication is technically feasible.
▪ There is growing international support to deliver effec-
tive measles vaccination programmes leading to the erad-
ication of measles in our lifetime.
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